AstraZeneca PLC (AZN)vsGalapagos NV ADR (GLPG)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
GLPG
Galapagos NV ADR
$27.86
-1.97%
HEALTHCARE · Cap: $1.91B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 5181% more annual revenue ($58.74B vs $1.11B). GLPG leads profitability with a 28.8% profit margin vs 17.4%. GLPG trades at a lower P/E of 5.0x. GLPG earns a higher WallStSmart Score of 74/100 (B).
AZN
Buy64
out of 100
Grade: C+
GLPG
Strong Buy74
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+89.3%
Fair Value
$316.70
Current Price
$27.86
$288.84 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Attractively priced relative to earnings
Strong operational efficiency at 88.0%
Revenue surging 1093.0% year-over-year
Earnings expanding 3036.0% YoY
Keeps 29 of every $100 in revenue as profit
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Trading at 9.6x book value
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : GLPG
The strongest argument for GLPG centers on P/E Ratio, Operating Margin, Revenue Growth. Profitability is solid with margins at 28.8% and operating margin at 88.0%. Revenue growth of 1093.0% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : GLPG
The primary concerns for GLPG are Price/Book, Market Cap, Free Cash Flow.
Key Dynamics to Monitor
AZN profiles as a value stock while GLPG is a growth play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.28 — expect wider price swings.
GLPG is growing revenue faster at 1093.0% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
GLPG scores higher overall (74/100 vs 64/100), backed by strong 28.8% margins and 1093.0% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Galapagos NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
Galapagos NV, a clinical-stage biotechnology company, discovers, develops and markets several small molecule drugs. The company is headquartered in Mechelen, Belgium.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?